DBV Technologies

The company's core technology is the Viaskin patch, a non-invasive daily patch designed to deliver small amounts of allergens, or antigens, to the immune system through intact skin. This method targets specific immune cells in the skin without the allergen entering the bloodstream, which minimizes the risk of severe systemic reactions. The primary business model centers on the research, development, and eventual commercialization of Viaskin-based products. As a clinical-stage company, its revenue is currently derived from partnerships and milestone payments, with future revenue expected from product sales upon regulatory approval. The company is publicly traded on the Euronext Paris and NASDAQ exchanges.

DBV's lead product candidate is Viaskin Peanut, aimed at treating peanut allergies in children. After facing a setback in 2020 with a Complete Response Letter from the U.S. Food and Drug Administration (FDA) due to concerns about patch adhesion, the company redesigned the product. Subsequent Phase 3 clinical trials, such as VITESSE and EPITOPE, have demonstrated statistically significant therapeutic effects in children aged 4-7 and toddlers aged 1-3. Based on these positive results, DBV Technologies plans to submit a Biologics License Application (BLA) to the FDA in 2026. The pipeline also includes Viaskin Milk for cow's milk protein allergy and early-stage research into treatments for other conditions like celiac disease.